
RE: MLSC Grants for Accelerators

From Orli Biger <Orli.Biger@arcinnovation.org>

Date Mon 11/10/2025 2:23 PM

To Audrey Medeiros <amedeiros@masslifesciences.com>; MLSC Industry Programs <MLSCIndustryPrograms@masslifesciences.com>

Cc Yonatan Keschner <ykeschner@arcinnovation.org>; Yonatan Keschner <ykesch@gmail.com>; ofira zloto <ozloto@gmail.com>

Hi Audrey,

Thank you for getting back to me.

I can meet you this Friday at 10:30 AM. Please send us a meeting invite and include my colleagues Ofira and Yonatan in case they will be able to join.

Thanks,
Orli.

Orli Biger

CEO, ARC US

ARC Innovation at Sheba Medical Center



Orli.biger@arcinnovation.org

Mobile: 972-50-7089362

+1-615-971-4979

From: Audrey Medeiros <amedeiros@masslifesciences.com>

Sent: Monday, November 10, 2025 12:56 PM

To: Orli Biger <Orli.Biger@arcinnovation.org>; MLSC Industry Programs <MLSCIndustryPrograms@masslifesciences.com>

Cc: Yonatan Keschner <ykeschner@arcinnovation.org>; Yonatan Keschner <ykesch@gmail.com>; ofira zloto <ozloto@gmail.com>

Subject: Re: MLSC Grants for Accelerators

Hi Orli,

Great to e-meet you! I'm happy to discuss the application for incubators/accelerators. Would you have time for a meeting this Friday 11/14? I have any time after 10 30am open to meet. If yes, I can send a meeting invite!

Best,
Audrey

Audrey (Medeiros) Byrne, PhD

Program Manager, Scientific Innovation & Strategic

Investments

M: 774.721.4816 | [Website:](http://Website:masslifesciences.com)

masslifesciences.com

Address: 1075 Main St Suite 100, Waltham MA

02451

Explore MLSC Funding Opportunities | [Learn more](#)

Become an expert reviewer for our programs | [Interest form](#)



From: Orli Biger <Orli.Biger@arcinnovation.org>

Sent: Monday, November 10, 2025 1:14 PM

To: Audrey Medeiros <amedeiros@masslifesciences.com>; MLSC Industry Programs <MLSCIndustryPrograms@masslifesciences.com>

Cc: Yonatan Keschner <ykeschner@arcinnovation.org>; Yonatan Keschner <ykesch@gmail.com>; ofira zloto <ozloto@gmail.com>

Subject: RE: MLSC Grants for Accelerators

+ One pager

Orli Biger

CEO, ARC US

ARC Innovation at Sheba Medical Center



Orli.biger@arcinnovation.org

Mobile: 972-50-7089362

+1-615-971-4979

From: Orli Biger
Sent: Monday, November 10, 2025 12 09 PM
To: 'info@masslifesciences.com' <info@masslifesciences.com>; 'amedeiros@masslifesciences.com' <amedeiros@masslifesciences.com>
Cc: Yonatan Keschner <ykeschner@arcinnovation.org>; 'Yonatan Keschner' <ykesch@gmail.com>; 'ofira zloto' <ozloto@gmail.com>
Subject: RE: MLSC Grants for Accelerators

Dear Audry,

I hope this message finds you well.

I recently joined the MLSC Roadshow webinar, and I am reaching out to inquire about potential grants that would be suitable for **accelerators in Massachusetts**.

We are currently building a soft-landing pad for international healthcare startups, with a particular focus on digital health and medical devices.

Our groundbreaking initiative has already garnered significant recognition, as highlighted in an announcement by Governor Healey.

You can read more about it here: <https://www.mass.gov/news/governor-healey-celebrates-shebaarcs-expansion-to-massachusetts>.

I have also attached a one-pager for your reference.

Your guidance and insights on suitable grants would be immensely valuable to us.

Thank you for your time and assistance.

Best regards,

Orli.

Orli Biger

CEO, ARC US

ARC Innovation at Sheba Medical Center



Orli.biger@arcinnovation.org

Mobile: 972-50-7089362

+1-615-971-4979

The information contained in this communication, including any attachments, is confidential and is intended only for the use of the recipient(s) named above. If the reader of this message is not an intended recipient, you are notified that any dissemination, distribution or copying of this communication is strictly prohibited. If you receive this communication in error, please notify the sender immediately, and delete the communication, any attachments, and all copies. While certain exceptions and/or exemptions may apply, Massachusetts Public Records Laws and the Federal Freedom of Information Act governs this communication.

RE: IMPORTANT: MLSC Research Infrastructure Application Revisions

From Orli Biger <Orli.Biger@arcinnovation.org>

Date Wed 12/10/2025 4:26 PM

To Carla Reimold <CReimold@masslifesciences.com>; ofira zloto <ozloto@gmail.com>; Audrey Medeiros <amedeiros@masslifesciences.com>

Cc Yonatan Keschner <ykeschner@arcinnovation.org>

 1 attachment (76 KB)

ARC Port Boston;

Dear Carla and Audrey,

I hope this email finds you well.

As a follow-up from our recent conversations, please find attached a confirmation email from our legal advisor stating that their office is actively working on the formation of ARC PORT Boston as a nonprofit organization based in Massachusetts.

We greatly appreciate your consideration of our application and kindly request the opportunity to edit the application as per your instructions.

Your assistance in temporarily reopening the application for revisions would be invaluable.

Thank you for your support and understanding.

Best regards,
Orli.

Orli Biger

CEO, ARC US

ARC Innovation at Sheba Medical Center



Orli.biger@arcinnovation.org

Mobile: 972-50-7089362

+1-615-971-4979

From: Carla Reimold <CReimold@masslifesciences.com>
Sent: Wednesday, December 10, 2025 11:22 AM
To: ofira zloto <ozloto@gmail.com>
Cc: Orli Biger <Orli.Biger@arcinnovation.org>; Audrey Medeiros <amedeiros@masslifesciences.com>
Subject: Re: IMPORTANT: MLSC Research Infrastructure Application Revisions

That works well for me. Speak soon!
Best,
Carla

Carla Reimold, PhD
Executive Vice President
Scientific Innovation and Strategic Investments

O: 781.373.7714 M: 781.296.9967



masslifesciences.com

1075 Main St Suite 100, Waltham MA 02451

From: ofira zloto <ozloto@gmail.com>
Sent: Wednesday, December 10, 2025 12:19 PM
To: Carla Reimold <CReimold@masslifesciences.com>
Cc: Orli Biger <Orli.Biger@arcinnovation.org>; Audrey Medeiros <amedeiros@masslifesciences.com>
Subject: Re: IMPORTANT: MLSC Research Infrastructure Application Revisions

Thank you. Can we speak at 13:00 o'clock today?
My phone number is-+16176089270

On Wed, 10 Dec 2025, 12:07 Carla Reimold, <CReimold@masslifesciences.com> wrote:

Dear Dr. Zloto,
Would you have time to hop on a quick call between 1pm and 4pm, to discuss?
Best,
Carla

Carla Reimold, PhD

Executive Vice President

Scientific Innovation and Strategic Investments

O: 781.373.7714

M: 781.296.9967



masslifesciences.com

1075 Main St Suite 100, Waltham MA 02451

From: ofira zloto <ozloto@gmail.com>
Sent: Wednesday, December 10, 2025 06:24
To: Audrey Medeiros <amedeiros@masslifesciences.com>
Cc: Orli Biger <Orli.Biger@arcinnovation.org>
Subject: Re: IMPORTANT: MLSC Research Infrastructure Application Revisions

Dear Audrey,

Thank you very much for your prompt reply.

Recently, our legal and administrative teams have been working to provide the required documentation confirming that ARC Boston will be eligible as a nonprofit entity. We expect to share this letter in the near future, in line with our previous conversation.

In the meantime, we have the three LOIs as requested (attached). In addition, we would like to update the Sharing/IP section (Section 7c) in accordance with the guidance provided during the webinar and e-mail, as well as make a few additional technical adjustments to the application.

Given this, I would greatly appreciate it if you could temporarily reopen the application for the next 24-48 hours so we can incorporate these revisions, with the understanding that the documentation will be required in order for the committee to consider the ARC Boston proposal.

Thank you again for your assistance.

Best regards,
Prof. Ofira Zloto

On Tue, Dec 9, 2025 at 5:14 PM Audrey Medeiros <amedeiros@masslifesciences.com> wrote:

Hi Dr. Zloto,

As we haven't received the documentation that you are an eligible nonprofit, we have not reopened your application for editing.

Best,
Audrey

Audrey (Medeiros) Byrne, PhD

Program Manager, Scientific Innovation & Strategic Investments

M: 774.721.4816 | **Website:**
masslifesciences.com

Address: 1075 Main St Suite 100, Waltham MA
02451

★ Explore MLSC Funding Opportunities | [Learn more](#)

📄 Become an expert reviewer for our programs | [Interest form](#)



From: ofira zloto <ozloto@gmail.com>
Sent: Monday, December 8, 2025 22:25
To: Audrey Medeiros <amedeiros@masslifesciences.com>
Cc: Orli Biger <Orli.Biger@arcinnovation.org>
Subject: Re: IMPORTANT: MLSC Research Infrastructure Application Revisions

Dear Audrey,

Thank you for the guidance provided in your recent email and during the webinar. I am working to implement all the relevant revisions to our Research Infrastructure application; however, the system does not allow me to make any edits, as the application status remains marked as "Received" (attached).

In order to proceed with the required updates, I kindly request that you change the status of our submission back to Draft (or otherwise reopen it for editing) and share the appropriate editable link.

Given that the revised submission deadline has been extended by MLSC to December 10, I would greatly appreciate your assistance as soon as possible so that we can ensure the application fully aligns with the program requirements.

Thank you,

Best regards,

Prof. Ofira Zloto

0016

Submitted to **Massachusetts Life Sciences Center - Research Infrastructure Program FY26** on Fri, Nov 21, 2025 1:34 PM

[Download](#) | [Withdraw](#) | [Transfer Ownership](#)

ACTIVITY | MESSAGES | FORMS | NOTE | AWARDS & PAYMENTS

Eligibility Form

No form submitted

Initial Form: Massachusetts Life Sciences Center

✓ Research Infrastructure Program FY26
Submitted on November 21, 2025

Applicant Name (Organization)

On Thu, Dec 4, 2025 at 6:32 PM Audrey Medeiros <amedeiros@masslifesciences.com> wrote:

Hi all,

In order to expand on the content of my previous Research Infrastructure application email, I will be holding two sessions to go over the content of the email in more detail. Please register for one of the below sessions:

- [Register for Friday December 5th from 12pm-12:30pm](#)
- [Register for Monday December 8th from 9am-9:30am](#)

I will be expanding on the points in my previous email and will only be answering general questions, not questions regarding anyone's specific applications. Hope to see you all there!

Best,
Audrey

Audrey (Medeiros) Byrne, PhD

Program Manager, Scientific Innovation & Strategic Investments

M: 774.721.4816 | **Website:**

masslifesciences.com

Address: 1075 Main St Suite 100, Waltham MA 02451

✨ Explore MLSC Funding Opportunities | [Learn more](#)

📄 Become an expert reviewer for our programs | [Interest form](#)



From: Audrey Medeiros <amedeiros@masslifesciences.com>

Sent: Wednesday, December 3, 2025 16:59

To: Audrey Medeiros <amedeiros@masslifesciences.com>

Cc: Meghan Davis <mdavis@masslifesciences.com>

Subject: IMPORTANT: MLSC Research Infrastructure Application Revisions

Dear Research Infrastructure Program Applicant,

This is a copy of the message just sent through Submittable. MLSC staff has briefly reviewed submitted applications to determine eligibility for the program. Several applications require attention on one or more of the below points. **This is a general email going out to all applicants, and it does not mean your specific application requires revision.** Nevertheless, please review your application and ensure it meets all of the following requirements:

1. Biosketch/CVs: Each CV should be no more than 2 pages. If you have more than 3 CVs, please remove the additional CVs.
2. Sharing/IP: Please ensure to check your sharing plan (7c).
 - a. The resource cannot be limited to your institution, region, or collaborators. This section should explicitly mention that it is available to all researchers internal and external.
 - b. Use of the resource cannot be prioritized based on subjective metrics like project impact.
 - c. This answer should include how research use will occur, either direct usage or on a fee-for-service basis.
 - d. There cannot be IP restrictions on user data.
3. Budgets:
 - a. Please ensure it is clear that everything in your budget is a capital expense. See the Funding section on the [Eligibility Requirements and Evaluation Webpage](#) for more details on what qualifies as a capital expense.
 - b. Service contracts are only allowable when purchased with the equipment. Service contracts and warranties purchased outside of the initial equipment purchase are not allowed and must be removed from budgets.
 - c. Please check your MLSC budget tables and ensure that there are no \$ or commas. Check to be sure the row 4 "Total Contribution" cell has added correctly.
4. Cost share: Breakdown of Expenditures: Academic Contributions and Industry Contributions
 - a. The committed amounts in these two tables need to be explicitly documented as committed funds in an attached letter (Letters of Commitment from Funding Sources). Letters of funding commitment are required to have the dollar amount committed in them, and this amount needs to match the contributions table.
 - b. These commitment letters are not commitments from users. Grants of users are not acceptable as contributions and need to be removed. NIH grants are only allowable as cost-share if they are purchasing equipment or supplies directly to build/augment the core.
 - c. Additional letters of Commitment that do not contain the financial support and any general letters of support need to be removed.
5. Letters of Interest: Letters of Interest from academic and industry partners are required to say that they would actually use the resource and what they would use it for.
 - a. Each letter of interest is required to contain the following two components:
 - i. That they would utilize the equipment/resource
 - ii. An example of what project they would utilize the resource for
 - b. Letters from equipment vendors are not acceptable as letters of interest unless that company is planning to be a user of the resource.
 - c. Letters from a Chief or Dean of a department that say generally that their department would use this resource are unacceptable. Departmental letters that include multiple PI's need to be clear what each group would use the resource for.

- d. Vague statements like "we look forward to collaborating with this resource" or "we would be interested in open communication" are unacceptable and need to make more clear that they would use the resource if funded.
- a. General letters of "enthusiastic support" must be deleted. Letters that do not qualify as Letters of Interest or Letters of Commitment for Funding must be removed.
- a. Only 3-5 letters for academic and 3-5 letters from industry sources are allowed. All additional letters must be removed.

If your application materials do not meet these criteria, your application cannot move forward to our external review panel.

Your application has been placed in draft mode and you will have the opportunity to amend your application until **Wednesday, December 10th** at 5:00 PM. Please amend your application and/or take this as an opportunity to double check that you've appropriately addressed each question and sub-question, as well as uploaded all required attachments.

If you have any questions, please feel free to contact me.

Best,
Audrey (Medeiros) Byrne

Audrey (Medeiros) Byrne, PhD

Program Manager, Scientific Innovation & Strategic Investments

M: 774.721.4816 | **Website:**
masslifesciences.com

Address: 1075 Main St Suite 100, Waltham MA
02451

★ Explore MLSC Funding Opportunities | [Learn more](#)
📄 Become an expert reviewer for our programs | [Interest form](#)



The information contained in this communication, including any attachments, is confidential and is intended only for the use of the recipient(s) named above. If the reader of this message is not an intended recipient, you are notified that any dissemination, distribution or copying of this communication is strictly prohibited. If you receive this communication in error, please notify the sender immediately, and delete the communication, any attachments, and all copies. While certain exceptions and/or exemptions may apply, Massachusetts Public Records Laws and the Federal Freedom of Information Act governs this communication.

The information contained in this communication, including any attachments, is confidential and is intended only for the use of the recipient(s) named above. If the reader of this message is not an intended recipient, you are notified that any dissemination, distribution or copying of this communication is strictly prohibited. If you receive this communication in error, please notify the sender immediately, and delete the communication, any attachments, and all copies. While certain exceptions and/or exemptions may apply,

Massachusetts Public Records Laws and the Federal Freedom of Information Act governs this communication.

The information contained in this communication, including any attachments, is confidential and is intended only for the use of the recipient(s) named above. If the reader of this message is not an intended recipient, you are notified that any dissemination, distribution or copying of this communication is strictly prohibited. If you receive this communication in error, please notify the sender immediately, and delete the communication, any attachments, and all copies. While certain exceptions and/or exemptions may apply, Massachusetts Public Records Laws and the Federal Freedom of Information Act governs this communication.

The information contained in this communication, including any attachments, is confidential and is intended only for the use of the recipient(s) named above. If the reader of this message is not an intended recipient, you are notified that any dissemination, distribution or copying of this communication is strictly prohibited. If you receive this communication in error, please notify the sender immediately, and delete the communication, any attachments, and all copies. While certain exceptions and/or exemptions may apply, Massachusetts Public Records Laws and the Federal Freedom of Information Act governs this communication.

Re: IMPORTANT: MLSC Research Infrastructure Application Revisions

From ofira zloto <ozloto@gmail.com>

Date Thu 12/25/2025 9:33 AM

To Carla Reimold <CReimold@masslifesciences.com>

Cc Audrey Medeiros <amedeiros@masslifesciences.com>; Yonatan Keschner <ykeschner@arcinnovation.org>

Dear Clara,

Thank you very much for the opportunity to apply for this grant and for your time and guidance throughout the process.

Following our recent conversation, and in light of the clarification that since we are currently unable to provide confirmation of our Massachusetts nonprofit legal status (though the legal team will have this in place by first week of January), as well as your recommendation to consider reapplying once our local entity is fully established, we have decided to withdraw our application at this time.

We greatly appreciate your transparency and advice, and we would welcome the opportunity to submit a new application in the upcoming cycle, as you suggested, once all required documentation is in place.

Thank you again for your support and consideration. Wishing you a happy holiday!

Warm regards,
Prof. Ofira Zloto

On Wed, Dec 10, 2025 at 7:22 PM Carla Reimold <CReimold@masslifesciences.com> wrote:

That works well for me. Speak soon!

Best,
Carla

Carla Reimold, PhD
Executive Vice President
Scientific Innovation and Strategic Investments
O: 781.373.7714 M: 781.296.9967

masslifesciences.com

1075 Main St Suite 100, Waltham MA 02451



From: ofira zloto <ozloto@gmail.com>

Sent: Wednesday, December 10, 2025 12:19 PM

To: Carla Reimold <CReimold@masslifesciences.com>

Cc: Orli Biger <Orli.Biger@arcinnovation.org>; Audrey Medeiros <amedeiros@masslifesciences.com>

Subject: Re: IMPORTANT: MLSC Research Infrastructure Application Revisions

Thank you. Can we speak at 13:00 o'clock today?

My phone number is-+16176089270

On Wed, 10 Dec 2025, 12:07 Carla Reimold, <CReimold@masslifesciences.com> wrote:

Dear Dr. Zloto,

Would you have time to hop on a quick call between 1pm and 4pm, to discuss?

Best,

Carla

Carla Reimold, PhD
Executive Vice President
Scientific Innovation and Strategic Investments
O: 781.373.7714 M: 781.296.9967



masslifesciences.com

1075 Main St Suite 100, Waltham MA 02451

From: ofira zloto <ozloto@gmail.com>

Sent: Wednesday, December 10, 2025 06:24

To: Audrey Medeiros <amedeiros@masslifesciences.com>

Cc: Orli Biger <Orli.Biger@arcinnovation.org>

Subject: Re: IMPORTANT: MLSC Research Infrastructure Application Revisions

Dear Audrey,

Thank you very much for your prompt reply.

Recently, our legal and administrative teams have been working to provide the required documentation confirming that ARC Boston will be eligible as a nonprofit entity. We expect to share this letter in the near future, in line with our previous conversation.

In the meantime, we have the three LOIs as requested (attached). In addition, we would like to update the Sharing/IP section (Section 7c) in accordance with the guidance provided during the webinar and e-mail, as well as make a few additional technical adjustments to the application. Given this, I would greatly appreciate it if you could temporarily reopen the application for the next 24-48 hours so we can incorporate these revisions, with the understanding that the documentation will be required in order for the committee to consider the ARC Boston proposal.

Thank you again for your assistance.

Best regards,

Prof. Ofira Zloto

On Tue, Dec 9, 2025 at 5:14 PM Audrey Medeiros <amedeiros@masslifesciences.com> wrote:

Hi Dr. Zloto,

As we haven't received the documentation that you are an eligible nonprofit, we have not reopened your application for editing.

Best,
Audrey

Audrey (Medeiros) Byrne, PhD

Program Manager, Scientific Innovation & Strategic Investments

M: 774.721.4816 | Website: masslifesciences.com

Address: 1075 Main St Suite 100, Waltham MA 02451

🌟 Explore MLSC Funding Opportunities | [Learn more](#)

📄 Become an expert reviewer for our programs | [Interest form](#)



From: ofira zloto <ozloto@gmail.com>
Sent: Monday, December 8, 2025 22:25
To: Audrey Medeiros <amedeiros@masslifesciences.com>
Cc: Orli Biger <Orli.Biger@arcinnovation.org>
Subject: Re: IMPORTANT: MLSC Research Infrastructure Application Revisions

Dear Audrey,

Thank you for the guidance provided in your recent email and during the webinar. I am working to implement all the relevant revisions to our Research Infrastructure application; however, the system does not allow me to make any edits, as the application status remains marked as "Received" (attached).

In order to proceed with the required updates, I kindly request that you change the status of our submission back to Draft (or otherwise reopen it for editing) and share the appropriate editable link.

Given that the revised submission deadline has been extended by MLSC to December 10, I would greatly appreciate your assistance as soon as possible so that we can ensure the application fully aligns with the program requirements.

Thank you,
Best regards,
Prof. Ofira Zloto

0016

Submitted to **Massachusetts Life Sciences Center - Research Infrastructure Program FY26** on Fri, Nov 21, 2025 1:34 PM

Received

[Download](#) | [Withdraw](#) | [Transfer Ownership](#)

ACTIVITY

MESSAGES

FORMS

NOTE

AWARDS & PAYMENTS

Eligibility Form

No form submitted

Initial Form: Massachusetts Life Sciences Center

✓ Research Infrastructure Program FY26

Submitted on November 21, 2025

Applicant Name (Organization)

On Thu, Dec 4, 2025 at 6:32 PM Audrey Medeiros <amedeiros@masslifesciences.com> wrote:
Hi all,

In order to expand on the content of my previous Research Infrastructure application email, I will be holding two sessions to go over the content of the email in more detail. Please register for one of the below sessions:

- [Register for Friday December 5th from 12pm-12:30pm](#)
- [Register for Monday December 8th from 9am-9:30am](#)

I will be expanding on the points in my previous email and will only be answering general questions, not questions regarding anyone's specific applications. Hope to see you all there!

Best,
Audrey

Audrey (Medeiros) Byrne, PhD

Program Manager, Scientific Innovation & Strategic Investments

M: 774.721.4816 | Website: masslifesciences.com

Address: 1075 Main St Suite 100, Waltham MA 02451

 Explore MLSC Funding Opportunities | [Learn more](#)
 Become an expert reviewer for our programs | [Interest form](#)



From: Audrey Medeiros <amedeiros@masslifesciences.com>
Sent: Wednesday, December 3, 2025 16:59
To: Audrey Medeiros <amedeiros@masslifesciences.com>
Cc: Meghan Davis <mdavis@masslifesciences.com>
Subject: IMPORTANT: MLSC Research Infrastructure Application Revisions

Dear Research Infrastructure Program Applicant,

This is a copy of the message just sent through Submittable. MLSC staff has briefly reviewed submitted applications to determine eligibility for the program. Several applications require attention on one or more of the below points. **This is a general email going out to all applicants, and it does not mean your specific application requires revision.** Nevertheless, please review your application and ensure it meets all of the following requirements:

1. Biosketch/CVs: Each CV should be no more than 2 pages. If you have more than 3 CVs, please remove the additional CVs.
2. Sharing/IP: Please ensure to check your sharing plan (7c).
 - a. The resource cannot be limited to your institution, region, or collaborators. This section should explicitly mention that it is available to all researchers internal and external.
 - b. Use of the resource cannot be prioritized based on subjective metrics like project impact.
 - c. This answer should include how research use will occur, either direct usage or on a fee-for-service basis.
 - d. There cannot be IP restrictions on user data.
3. Budgets:

- a. Please ensure it is clear that everything in your budget is a capital expense. See the Funding section on the [Eligibility Requirements and Evaluation Webpage](#) for more details on what qualifies as a capital expense.
 - b. Service contracts are only allowable when purchased with the equipment. Service contracts and warranties purchased outside of the initial equipment purchase are not allowed and must be removed from budgets.
 - c. Please check your MLSC budget tables and ensure that there are no \$ or commas. Check to be sure the row 4 "Total Contribution" cell has added correctly.
4. Cost share: Breakdown of Expenditures: Academic Contributions and Industry Contributions
 - a. The committed amounts in these two tables need to be explicitly documented as committed funds in an attached letter (Letters of Commitment from Funding Sources). Letters of funding commitment are required to have the dollar amount committed in them, and this amount needs to match the contributions table.
 - b. These commitment letters are not commitments from users. Grants of users are not acceptable as contributions and need to be removed. NIH grants are only allowable as cost-share if they are purchasing equipment or supplies directly to build/augment the core.
 - c. Additional letters of Commitment that do not contain the financial support and any general letters of support need to be removed.
5. Letters of Interest: Letters of Interest from academic and industry partners are required to say that they would actually use the resource and what they would use it for.
 - a. Each letter of interest is required to contain the following two components:
 - i. That they would utilize the equipment/resource
 - ii. An example of what project they would utilize the resource for
 - b. Letters from equipment vendors are not acceptable as letters of interest unless that company is planning to be a user of the resource.
 - c. Letters from a Chief or Dean of a department that say generally that their department would use this resource are unacceptable. Departmental letters that include multiple PI's need to be clear what each group would use the resource for.
 - d. Vague statements like "we look forward to collaborating with this resource" or "we would be interested in open communication" are unacceptable and need to make more clear that they would use the resource if funded.
 - a. General letters of "enthusiastic support" must be deleted. Letters that do not qualify as Letters of Interest or Letters of Commitment for Funding must be removed.
 - a. Only 3-5 letters for academic and 3-5 letters from industry sources are allowed. All additional letters must be removed.

If your application materials do not meet these criteria, your application cannot move forward to our external review panel.

Your application has been placed in draft mode and you will have the opportunity to amend your application until **Wednesday, December 10th** at 5:00 PM. Please amend your application and/or take this as an opportunity to double check that you've appropriately addressed each question and sub-question, as well as uploaded all required attachments.

If you have any questions, please feel free to contact me.

Best,
Audrey (Medeiros) Byrne

Audrey (Medeiros) Byrne, PhD

Program Manager, Scientific Innovation & Strategic Investments

M: 774.721.4816 | Website: masslifesciences.com

Address: 1075 Main St Suite 100, Waltham MA 02451

 Explore MLSC Funding Opportunities | [Learn more](#)
 Become an expert reviewer for our programs | [Interest form](#)



The information contained in this communication, including any attachments, is confidential and is intended only for the use of the recipient(s) named above. If the reader of this message is not an intended recipient, you are notified that any dissemination, distribution or copying of this communication is strictly prohibited. If you receive this communication in error, please notify the sender immediately, and delete the communication, any attachments, and all copies. While certain exceptions and/or exemptions may apply, Massachusetts Public Records Laws and the Federal Freedom of Information Act governs this communication.

The information contained in this communication, including any attachments, is confidential and is intended only for the use of the recipient(s) named above. If the reader of this message is not an intended recipient, you are notified that any dissemination, distribution or copying of this communication is strictly prohibited. If you receive this communication in error, please notify the sender immediately, and delete the communication, any attachments, and all copies. While certain exceptions and/or exemptions may apply, Massachusetts Public Records Laws and the Federal Freedom of Information Act governs this communication.

The information contained in this communication, including any attachments, is confidential and is intended only for the use of the recipient(s) named above. If the reader of this message is not an intended recipient, you are notified that any dissemination, distribution or copying of this communication is strictly prohibited. If you receive this communication in error, please notify the sender immediately, and delete the communication, any attachments, and all copies. While certain exceptions and/or exemptions may apply, Massachusetts Public Records Laws and the Federal Freedom of Information Act governs this communication.

The information contained in this communication, including any attachments, is confidential and is intended only for the use of the recipient(s) named above. If the reader of this message is not an intended recipient, you are notified that any dissemination, distribution or copying of this communication is strictly prohibited. If you receive this communication in error, please notify the sender immediately, and delete the communication, any attachments, and all copies. While certain exceptions and/or exemptions may apply, Massachusetts Public Records Laws and the Federal Freedom of Information Act governs this communication.

RE: MLSC Grants for Accelerators

From Orli Biger <Orli.Biger@arcinnovation.org>

Date Mon 2025-11-10 2:23 PM

To Audrey Medeiros <amedeiros@masslifesciences.com>; MLSC Industry Programs
<MLSCIndustryPrograms@masslifesciences.com>

Cc Yonatan Keschner <ykeschner@arcinnovation.org>; Yonatan Keschner <ykesch@gmail.com>; ofira zloto
<ozloto@gmail.com>

Hi Audrey,

Thank you for getting back to me.

I can meet you this Friday at 10:30 AM. Please send us a meeting invite and include my colleagues Ofira and Yonatan in case they will be able to join.

Thanks,
Orli.

Orli Biger

CEO, ARC US

ARC Innovation at Sheba Medical Center



Orli.biger@arcinnovation.org

Mobile: 972-50-7089362

+1-615-971-4979

From: Audrey Medeiros <amedeiros@masslifesciences.com>

Sent: Monday, November 10, 2025 12:56 PM

To: Orli Biger <Orli.Biger@arcinnovation.org>; MLSC Industry Programs
<MLSCIndustryPrograms@masslifesciences.com>

Cc: Yonatan Keschner <ykeschner@arcinnovation.org>; Yonatan Keschner <ykesch@gmail.com>; ofira zloto
<ozloto@gmail.com>

Subject: Re: MLSC Grants for Accelerators

Hi Orli,

Great to e-meet you! I'm happy to discuss the application for incubators/accelerators. Would you have time for a meeting this Friday 11/14? I have any time after 10:30am open to meet. If yes, I can send a

meeting invite!

Best,
Audrey

Audrey (Medeiros) Byrne, PhD

Program Manager, Scientific Innovation & Strategic
Investments

M: 774.721.4816 | **Website:**

masslifesciences.com

Address: 1075 Main St Suite 100, Waltham MA
02451

Explore MLSC Funding Opportunities | [Learn more](#)

Become an expert reviewer for our programs | [Interest form](#)



From: Orli Biger <Orli.Biger@arcinnovation.org>

Sent: Monday, November 10, 2025 1:14 PM

To: Audrey Medeiros <amedeiros@masslifesciences.com>; MLSC Industry Programs
<MLSCIndustryPrograms@masslifesciences.com>

Cc: Yonatan Keschner <ykeschner@arcinnovation.org>; Yonatan Keschner <ykesch@gmail.com>; ofira zloto
<ozloto@gmail.com>

Subject: RE: MLSC Grants for Accelerators

+ One pager

Orli Biger

CEO, ARC US

ARC Innovation at Sheba Medical Center



Orli.biger@arcinnovation.org

Mobile: 972-50-7089362

+1-615-971-4979

From: Orli Biger

Sent: Monday, November 10, 2025 12:09 PM

To: 'info@masslifesciences.com' <info@masslifesciences.com>; 'amedeiros@masslifesciences.com'
<amedeiros@masslifesciences.com>

Cc: Yonatan Keschner <ykeschner@arcinnovation.org>; 'Yonatan Keschner' <ykesch@gmail.com>; 'ofira zloto'

<ozloto@gmail.com>

Subject: RE: MLSC Grants for Accelerators

Dear Audry,

I hope this message finds you well.

I recently joined the MLSC Roadshow webinar, and I am reaching out to inquire about potential grants that would be suitable for **accelerators in Massachusetts**.

We are currently building a soft-landing pad for international healthcare startups, with a particular focus on digital health and medical devices.

Our groundbreaking initiative has already garnered significant recognition, as highlighted in an announcement by Governor Healey.

You can read more about it here: <https://www.mass.gov/news/governor-healey-celebrates-shebaarcs-expansion-to-massachusetts>.

I have also attached a one-pager for your reference.

Your guidance and insights on suitable grants would be immensely valuable to us.

Thank you for your time and assistance.

Best regards,

Orli.

Orli Biger

CEO, ARC US

ARC Innovation at Sheba Medical Center



Orli.biger@arcinnovation.org

Mobile: 972-50-7089362

+1-615-971-4979

The information contained in this communication, including any attachments, is confidential and is intended only for the use of the recipient(s) named above. If the reader of this message is not an intended recipient, you are notified that any dissemination, distribution or copying of this communication is strictly prohibited. If you receive this communication in error, please notify the sender immediately, and delete the communication, any attachments, and all copies. While certain exceptions and/or exemptions may apply, Massachusetts Public Records Laws and the Federal Freedom of Information Act governs this communication.

Hawa Fall

From: Political - Consulate General of ISRAEL in Boston <Political@boston.mfa.gov.il>
Sent: Wednesday, November 5, 2025 10:56 AM
To: Hawa Fall
Subject: Personal Invitation from Consul General Benny Sharoni



Dear Hawa,

I am pleased to invite you to an exclusive, fully funded study tour to Israel, specifically designed for New England political staff members.

The tour will take place from **December 6-12, 2025**, and is hosted by the State of Israel's Ministry of Foreign Affairs.

This delegation will provide an in-depth look at Israel's unique character, offering firsthand insights into the country's history, culture, and resilience following the events of October 7th.

The program will include briefings and meetings with officials, security experts and civil society organizations, offering a comprehensive view of Israel's current challenges and future prospects.

You will also have the opportunity to engage with key figures from Israel's world-class innovation hub.

With the highest number of startups per capita in the world, this trip will provide a chance to explore opportunities for strengthening innovation and commercial partnerships between Israel and New England.

In addition to these professional engagements, you will experience Israel's rich cultural tapestry.

The itinerary includes visits to Jerusalem, where you will explore sites sacred to Christianity, Judaism and Islam, and gain insights into societal initiatives that promote coexistence among Israel's diverse communities. You will also enjoy Israel's diverse cuisine and its vibrant cultural scene.

The expenses of this trip are fully covered by Israel's Foreign Ministry. This includes economy-class airfare to Tel Aviv, in-country transportation, accommodations, meals, professional guides, and more.

Space is limited, so please RSVP to Erin Gubert at political@boston.mfa.gov.il by **Monday, November 10, 2025**. For any additional information, please feel free to contact Erin Gubert at the email above.

We hope you can join this delegation for an enriching and meaningful experience and look forward to your response.

Sincerely,

Benjamin (Benny) Sharoni
Consul General of Israel to New England

Consul General Benjamin Sharoni

Consulate General of Israel to New England
20 Park Plaza #1020 Boston, MA 02116



MLSC - ARC Meeting

Organizer Audrey Medeiros <amedeiros@masslifesciences.com>
Meeting time This event occurred 1 month ago (Fri 2025-11-14 10:30 AM - 11:00 AM)
Location Microsoft Teams Meeting
My response Accepted
Required attendees Orli.Biger@arcinnovation.org, ykeschner@arcinnovation.org, ozloto@gmail.com
Message sent Mon 2025-11-10 2:28 PM

Microsoft Teams [Need help?](#)

[Join the meeting now](#)

Meeting ID: 216 014 366 796 36

Passcode: CG92UQ2X

Dial in by phone

[+1 929 346 7262,,623932039#](#) United States, New York City

[Find a local number](#)

Phone conference ID: 623 932 039#

For organizers: [Meeting options](#) | [Reset dial in PIN](#)

RE: ARC Boston - MLSC Infrastructure Grant

From Orli Biger <Orli.Biger@arcinnovation.org>

Date Wed 2025-11-19 1:11 PM

To Audrey Medeiros <amedeiros@masslifesciences.com>

Cc ofira zloto <ozloto@gmail.com>; Yonatan Keschner <ykeschner@arcinnovation.org>; Yonatan Keschner <ykesch@gmail.com>

Thank you, Audrey!

Orli Biger

CEO, ARC US

ARC Innovation at Sheba Medical Center



Orli.biger@arcinnovation.org

Mobile: 972-50-7089362

+1-615-971-4979

From: Audrey Medeiros <amedeiros@masslifesciences.com>

Sent: Wednesday, November 19, 2025 9:13 AM

To: Orli Biger <Orli.Biger@arcinnovation.org>

Cc: ofira zloto <ozloto@gmail.com>; Yonatan Keschner <ykeschner@arcinnovation.org>; Yonatan Keschner <ykesch@gmail.com>

Subject: Re: ARC Boston - MLSC Infrastructure Grant

Hi Orli,

You are able to submit the Research Infrastructure application on the Nov. 21st deadline while you are in the process of your MA non-profit application process. However, you must have the non-profit status completed by the end of our internal administrative review of the applications for your proposal to move forward with the external review panel.

Please send me a copy of your application for non-profit status via email (since there is not a place to upload it on the Research Infrastructure application). Importantly, please email me a copy of the official notice of non-profit status as soon as it comes in.

Best,

Audrey

Audrey (Medeiros) Byrne, PhD

Program Manager, Scientific Innovation & Strategic Investments

M: 774.721.4816 | **Website:**

masslifesciences.com

Address: 1075 Main St Suite 100, Waltham MA 02451

Explore MLSC Funding Opportunities | [Learn more](#)

Become an expert reviewer for our programs | [Interest form](#)



From: Orli Biger <Orli.Biger@arcinnovation.org>

Sent: Wednesday, November 19, 2025 09:28

To: Audrey Medeiros <amedeiros@masslifesciences.com>

Cc: ofira zloto <ozloto@gmail.com>; Yonatan Keschner <ykeschner@arcinnovation.org>; Yonatan Keschner <ykesch@gmail.com>

Subject: ARC Boston - MLSC Infrastructure Grant

Dear Audrey,

I hope this email finds you well.

Thank you for the productive call on Friday

Following our conversation, we have decided to move forward with submitting the infrastructure grant application, which has a deadline of November 21.

Could you please let us know if we are able to submit, given that we are currently in the process of establishing a MASS-based non-profit entity?

I have attached the commitment letter we received from MLSC, signed by Kirk Taylor, M.D., President and CEO, Massachusetts Life Sciences Center, for your reference.

Thank you again for your support and assistance.

Best regards,
Orli.

Orli Biger

CEO, ARC US

ARC Innovation at Sheba Medical Center



Orli.biger@arcinnovation.org

Mobile: 972-50-7089362

+1-615-971-4979

The information contained in this communication, including any attachments, is confidential and is intended only for the use of the recipient(s) named above. If the reader of this message is not an intended recipient, you are notified that any dissemination, distribution or copying of this communication is strictly prohibited. If you receive this communication in error, please notify the sender immediately, and delete the communication, any attachments, and all copies. While certain exceptions and/or exemptions may apply, Massachusetts Public Records Laws and the Federal Freedom of Information Act governs this communication.

Re: ARC Boston - MLSC Infrastructure Grant

From Audrey Medeiros <amedeiros@masslifesciences.com>

Date Thu 2025-12-04 2:26 PM

To Orli Biger <Orli.Biger@arcinnovation.org>

Cc ofira zloto <ozloto@gmail.com>; Yonatan Keschner <ykeschner@arcinnovation.org>; Yonatan Keschner <ykesch@gmail.com>

Hi Orli,

The Research Infrastructure awards begin July 1, 2026 and function on a reimbursement basis. Only invoices that are dated after July 1, 2026 are eligible to be reimbursed through this award. I hope this helps!

Best,
Audrey

Audrey (Medeiros) Byrne, PhD

Program Manager, Scientific Innovation & Strategic Investments

M: 774.721.4816 | **Website:** masslifesciences.com

Address: 1075 Main St Suite 100, Waltham MA 02451

Explore MLSC Funding Opportunities | [Learn more](#)

Become an expert reviewer for our programs | [Interest form](#)



From: Orli Biger <Orli.Biger@arcinnovation.org>

Sent: Thursday, December 4, 2025 14:04

To: Audrey Medeiros <amedeiros@masslifesciences.com>

Cc: ofira zloto <ozloto@gmail.com>; Yonatan Keschner <ykeschner@arcinnovation.org>; Yonatan Keschner <ykesch@gmail.com>

Subject: RE: ARC Boston - MLSC Infrastructure Grant

Dear Audrey,

I hope this email finds you well.

As you know, we are in the process of opening a non-for-profit organization in Massachusetts, and we will send you a copy of the application as soon as possible. We have also submitted our application for the Research Infrastructure grant on November 21st.

Could you please elaborate on what we can expect to receive from the Massachusetts Life Sciences Center (MLSC) if we are successful in winning the grant?

Specifically, we are interested in understanding what our commitments would be and whether MLSC would transfer money to us or purchase equipment on our behalf.

Thank you for your assistance and support.

Best regards,
Orli.

Orli Biger

CEO, ARC US

ARC Innovation at Sheba Medical Center



Orli.biger@arcinnovation.org

Mobile: 972-50-7089362

+1-615-971-4979

From: Audrey Medeiros <amedeiros@masslifesciences.com>

Sent: Wednesday, November 19, 2025 9:13 AM

To: Orli Biger <Orli.Biger@arcinnovation.org>

Cc: ofira zloto <ozloto@gmail.com>; Yonatan Keschner <ykeschner@arcinnovation.org>; Yonatan Keschner <ykesch@gmail.com>

Subject: Re: ARC Boston - MLSC Infrastructure Grant

Hi Orli,

You are able to submit the Research Infrastructure application on the Nov. 21st deadline while you are in the process of your MA non-profit application process. However, you must have the non-profit status completed by the end of our internal administrative review of the applications for your proposal to move forward with the external review panel.

Please send me a copy of your application for non-profit status via email (since there is not a place to upload it on the Research Infrastructure application). Importantly, please email me a copy of the official notice of non-profit status as soon as it comes in.

Best,
Audrey

Audrey (Medeiros) Byrne, PhD

Program Manager, Scientific Innovation & Strategic
Investments

M: 774.721.4816 | **Website:**

masslifesciences.com

Address: 1075 Main St Suite 100, Waltham MA
02451



From: Orli Biger <Orli.Biger@arcinnovation.org>
Sent: Wednesday, November 19, 2025 09:28
To: Audrey Medeiros <amedeiros@masslifesciences.com>
Cc: ofira zloto <ozloto@gmail.com>; Yonatan Keschner <ykeschner@arcinnovation.org>; Yonatan Keschner <ykesch@gmail.com>
Subject: ARC Boston - MLSC Infrastructure Grant

Dear Audrey,

I hope this email finds you well.

Thank you for the productive call on Friday
Following our conversation, we have decided to move forward with submitting the infrastructure grant application, which has a deadline of November 21.

Could you please let us know if we are able to submit, given that we are currently in the process of establishing a MASS-based non-profit entity?

I have attached the commitment letter we received from MLSC, signed by Kirk Taylor, M.D., President and CEO, Massachusetts Life Sciences Center, for your reference.

Thank you again for your support and assistance.

Best regards,
Orli.

Orli Biger

CEO, ARC US

ARC Innovation at Sheba Medical Center



Orli.biger@arcinnovation.org

Mobile: 972-50-7089362

+1-615-971-4979

The information contained in this communication, including any attachments, is confidential and is intended only for the use of the recipient(s) named above. If the reader of this message is not an intended recipient, you are notified that any dissemination, distribution or copying of this communication is strictly prohibited. If you receive this communication in error, please notify the

sender immediately, and delete the communication, any attachments, and all copies. While certain exceptions and/or exemptions may apply, Massachusetts Public Records Laws and the Federal Freedom of Information Act governs this communication.

RE: MLSC Grants for Accelerators

From Orli Biger <Orli.Biger@arcinnovation.org>

Date Mon 2025-11-10 2:23 PM

To Audrey Medeiros <amedeiros@masslifesciences.com>; MLSC Industry Programs
<MLSCIndustryPrograms@masslifesciences.com>

Cc Yonatan Keschner <ykeschner@arcinnovation.org>; Yonatan Keschner <ykesch@gmail.com>; ofira zloto
<ozloto@gmail.com>

Hi Audrey,

Thank you for getting back to me.

I can meet you this Friday at 10:30 AM. Please send us a meeting invite and include my colleagues Ofira and Yonatan in case they will be able to join.

Thanks,
Orli.

Orli Biger

CEO, ARC US

ARC Innovation at Sheba Medical Center



Orli.biger@arcinnovation.org

Mobile: 972-50-7089362

+1-615-971-4979

From: Audrey Medeiros <amedeiros@masslifesciences.com>

Sent: Monday, November 10, 2025 12:56 PM

To: Orli Biger <Orli.Biger@arcinnovation.org>; MLSC Industry Programs
<MLSCIndustryPrograms@masslifesciences.com>

Cc: Yonatan Keschner <ykeschner@arcinnovation.org>; Yonatan Keschner <ykesch@gmail.com>; ofira zloto
<ozloto@gmail.com>

Subject: Re: MLSC Grants for Accelerators

Hi Orli,

Great to e-meet you! I'm happy to discuss the application for incubators/accelerators. Would you have time for a meeting this Friday 11/14? I have any time after 10:30am open to meet. If yes, I can send a

meeting invite!

Best,
Audrey

Audrey (Medeiros) Byrne, PhD

Program Manager, Scientific Innovation & Strategic
Investments

M: 774.721.4816 | **Website:**

masslifesciences.com

Address: 1075 Main St Suite 100, Waltham MA
02451

Explore MLSC Funding Opportunities | [Learn more](#)

Become an expert reviewer for our programs | [Interest form](#)



From: Orli Biger <Orli.Biger@arcinnovation.org>

Sent: Monday, November 10, 2025 1:14 PM

To: Audrey Medeiros <amedeiros@masslifesciences.com>; MLSC Industry Programs
<MLSCIndustryPrograms@masslifesciences.com>

Cc: Yonatan Keschner <ykeschner@arcinnovation.org>; Yonatan Keschner <ykesch@gmail.com>; ofira zloto
<ozloto@gmail.com>

Subject: RE: MLSC Grants for Accelerators

+ One pager

Orli Biger

CEO, ARC US

ARC Innovation at Sheba Medical Center



Orli.biger@arcinnovation.org

Mobile: 972-50-7089362

+1-615-971-4979

From: Orli Biger

Sent: Monday, November 10, 2025 12:09 PM

To: 'info@masslifesciences.com' <info@masslifesciences.com>; 'amedeiros@masslifesciences.com'
<amedeiros@masslifesciences.com>

Cc: Yonatan Keschner <ykeschner@arcinnovation.org>; 'Yonatan Keschner' <ykesch@gmail.com>; 'ofira zloto'

<ozloto@gmail.com>

Subject: RE: MLSC Grants for Accelerators

Dear Audry,

I hope this message finds you well.

I recently joined the MLSC Roadshow webinar, and I am reaching out to inquire about potential grants that would be suitable for **accelerators in Massachusetts**.

We are currently building a soft-landing pad for international healthcare startups, with a particular focus on digital health and medical devices.

Our groundbreaking initiative has already garnered significant recognition, as highlighted in an announcement by Governor Healey.

You can read more about it here: <https://www.mass.gov/news/governor-healey-celebrates-shebaarcs-expansion-to-massachusetts>.

I have also attached a one-pager for your reference.

Your guidance and insights on suitable grants would be immensely valuable to us.

Thank you for your time and assistance.

Best regards,

Orli.

Orli Biger

CEO, ARC US

ARC Innovation at Sheba Medical Center



Orli.biger@arcinnovation.org

Mobile: 972-50-7089362

+1-615-971-4979

The information contained in this communication, including any attachments, is confidential and is intended only for the use of the recipient(s) named above. If the reader of this message is not an intended recipient, you are notified that any dissemination, distribution or copying of this communication is strictly prohibited. If you receive this communication in error, please notify the sender immediately, and delete the communication, any attachments, and all copies. While certain exceptions and/or exemptions may apply, Massachusetts Public Records Laws and the Federal Freedom of Information Act governs this communication.

Re: IMPORTANT: MLSC Research Infrastructure Application Revisions

From ofira zloto <ozloto@gmail.com>

Date Thu 2025-12-25 9:33 AM

To Carla Reimold <CReimold@masslifesciences.com>

Cc Audrey Medeiros <amedeiros@masslifesciences.com>; Yonatan Keschner <ykeschner@arcinnovation.org>

Dear Clara,

Thank you very much for the opportunity to apply for this grant and for your time and guidance throughout the process.

Following our recent conversation, and in light of the clarification that since we are currently unable to provide confirmation of our Massachusetts nonprofit legal status (though the legal team will have this in place by first week of January), as well as your recommendation to consider reapplying once our local entity is fully established, we have decided to withdraw our application at this time.

We greatly appreciate your transparency and advice, and we would welcome the opportunity to submit a new application in the upcoming cycle, as you suggested, once all required documentation is in place.

Thank you again for your support and consideration. Wishing you a happy holiday!

Warm regards,
Prof. Ofira Zloto

On Wed, Dec 10, 2025 at 7:22 PM Carla Reimold <CReimold@masslifesciences.com> wrote:

That works well for me. Speak soon!

Best,
Carla

Carla Reimold, PhD

Executive Vice President
Scientific Innovation and Strategic Investments

O: 781.373.7714

M: 781.296.9967

masslifesciences.com

1075 Main St Suite 100, Waltham MA 02451



From: ofira zloto <ozloto@gmail.com>

Sent: Wednesday, December 10, 2025 12:19 PM

To: Carla Reimold <CReimold@masslifesciences.com>

Cc: Orli Biger <Orli.Biger@arcinnovation.org>; Audrey Medeiros <amedeiros@masslifesciences.com>

Subject: Re: IMPORTANT: MLSC Research Infrastructure Application Revisions

Thank you. Can we speak at 13:00 o'clock today?

My phone number is-+16176089270

On Wed, 10 Dec 2025, 12:07 Carla Reimold, <CReimold@masslifesciences.com> wrote:

Dear Dr. Zloto,

Would you have time to hop on a quick call between 1pm and 4pm, to discuss?

Best,

Carla

Carla Reimold, PhD

Executive Vice President

Scientific Innovation and Strategic Investments

O: 781.373.7714

M: 781.296.9967

masslifesciences.com

1075 Main St Suite 100, Waltham MA 02451



From: ofira zloto <ozloto@gmail.com>

Sent: Wednesday, December 10, 2025 06:24

To: Audrey Medeiros <amedeiros@masslifesciences.com>

Cc: Orli Biger <Orli.Biger@arcinnovation.org>

Subject: Re: IMPORTANT: MLSC Research Infrastructure Application Revisions

Dear Audrey,

Thank you very much for your prompt reply.

Recently, our legal and administrative teams have been working to provide the required documentation confirming that ARC Boston will be eligible as a nonprofit entity. We expect to share this letter in the near future, in line with our previous conversation.

In the meantime, we have the three LOIs as requested (attached). In addition, we would like to update the Sharing/IP section (Section 7c) in accordance with the guidance provided during the webinar and e mail, as well as make a few additional technical adjustments to the application. Given this, I would greatly appreciate it if you could temporarily reopen the application for the next 24 48 hours so we can incorporate these revisions, with the understanding that the documentation will be required in order for the committee to consider the ARC Boston proposal.

Thank you again for your assistance.

Best regards,

Prof. Ofira Zloto

On Tue, Dec 9, 2025 at 5:14 PM Audrey Medeiros <amedeiros@masslifesciences.com> wrote:

Hi Dr. Zloto,

As we haven't received the documentation that you are an eligible nonprofit, we have not reopened your application for editing.

Best,
Audrey

Audrey (Medeiros) Byrne, PhD
Program Manager, Scientific Innovation & Strategic Investments
M: 774.721.4816 | **Website:** masslifesciences.com
Address: 1075 Main St Suite 100, Waltham MA 02451

Explore MLSC Funding Opportunities | [Learn more](#)
Become an expert reviewer for our programs | [Interest form](#)



From: ofira zloto <ozloto@gmail.com>
Sent: Monday, December 8, 2025 22:25
To: Audrey Medeiros <amedeiros@masslifesciences.com>
Cc: Orli Biger <Orli.Biger@arcinnovation.org>
Subject: Re: IMPORTANT: MLSC Research Infrastructure Application Revisions

Dear Audrey,

Thank you for the guidance provided in your recent email and during the webinar. I am working to implement all the relevant revisions to our Research Infrastructure application; however, the system does not allow me to make any edits, as the application status remains marked as "Received" (attached).

In order to proceed with the required updates, I kindly request that you change the status of our submission back to Draft (or otherwise reopen it for editing) and share the appropriate editable link.

Given that the revised submission deadline has been extended by MLSC to December 10, I would greatly appreciate your assistance as soon as possible so that we can ensure the application fully aligns with the program requirements.

Thank you,
Best regards,
Prof. Ofira Zloto

0016

Submitted to **Massachusetts Life Sciences Center - Research Infrastructure Program FY26** on Fri, Nov 21, 2025 1:34 PM

Received

[Download](#) | [Withdraw](#) | [Transfer Ownership](#)

ACTIVITY | MESSAGES | FORMS | NOTE | AWARDS & PAYMENTS

Eligibility Form

No form submitted

Initial Form: Massachusetts Life Sciences Center

Research Infrastructure Program FY26

Submitted on November 21, 2025

Applicant Name (Organization)

On Thu, Dec 4, 2025 at 6:32 PM Audrey Medeiros <amedeiros@masslifesciences.com> wrote:
Hi all,

In order to expand on the content of my previous Research Infrastructure application email, I will be holding two sessions to go over the content of the email in more detail. Please register for one of the below sessions:

- [Register for Friday December 5th from 12pm-12:30pm](#)
- [Register for Monday December 8th from 9am-9:30am](#)

I will be expanding on the points in my previous email and will only be answering general questions, not questions regarding anyone's specific applications. Hope to see you all there!

Best,
Audrey

Audrey (Medeiros) Byrne, PhD

Program Manager, Scientific Innovation & Strategic Investments

M: 774.721.4816 | Website: masslifesciences.com

Address: 1075 Main St Suite 100, Waltham MA 02451

Explore MLSC Funding Opportunities | [Learn more](#)
Become an expert reviewer for our programs | [Interest form](#)



From: Audrey Medeiros <amedeiros@masslifesciences.com>
Sent: Wednesday, December 3, 2025 16:59
To: Audrey Medeiros <amedeiros@masslifesciences.com>
Cc: Meghan Davis <mdavis@masslifesciences.com>
Subject: IMPORTANT: MLSC Research Infrastructure Application Revisions

Dear Research Infrastructure Program Applicant,

This is a copy of the message just sent through Submittable. MLSC staff has briefly reviewed submitted applications to determine eligibility for the program. Several applications require attention on one or more of the below points. **This is a general email going out to all applicants, and it does not mean your specific application requires revision.** Nevertheless, please review your application and ensure it meets all of the following requirements:

1. Biosketch/CVs: Each CV should be no more than 2 pages. If you have more than 3 CVs, please remove the additional CVs.
2. Sharing/IP: Please ensure to check your sharing plan (7c).
 - a. The resource cannot be limited to your institution, region, or collaborators. This section should explicitly mention that it is available to all researchers internal and external.
 - b. Use of the resource cannot be prioritized based on subjective metrics like project impact.
 - c. This answer should include how research use will occur, either direct usage or on a fee-for-service basis.
 - d. There cannot be IP restrictions on user data.
3. Budgets:

- a. Please ensure it is clear that everything in your budget is a capital expense. See the Funding section on the [Eligibility Requirements and Evaluation Webpage](#) for more details on what qualifies as a capital expense.
- b. Service contracts are only allowable when purchased with the equipment. Service contracts and warranties purchased outside of the initial equipment purchase are not allowed and must be removed from budgets.
- c. Please check your MLSC budget tables and ensure that there are no \$ or commas. Check to be sure the row 4 "Total Contribution" cell has added correctly.
4. Cost share: Breakdown of Expenditures: Academic Contributions and Industry Contributions
 - a. The committed amounts in these two tables need to be explicitly documented as committed funds in an attached letter (Letters of Commitment from Funding Sources). Letters of funding commitment are required to have the dollar amount committed in them, and this amount needs to match the contributions table.
 - b. These commitment letters are not commitments from users. Grants of users are not acceptable as contributions and need to be removed. NIH grants are only allowable as cost-share if they are purchasing equipment or supplies directly to build/augment the core.
 - c. Additional letters of Commitment that do not contain the financial support and any general letters of support need to be removed.
5. Letters of Interest: Letters of Interest from academic and industry partners are required to say that they would actually use the resource and what they would use it for.
 - a. Each letter of interest is required to contain the following two components:
 - i. That they would utilize the equipment/resource
 - ii. An example of what project they would utilize the resource for
 - b. Letters from equipment vendors are not acceptable as letters of interest unless that company is planning to be a user of the resource.
 - c. Letters from a Chief or Dean of a department that say generally that their department would use this resource are unacceptable. Departmental letters that include multiple PI's need to be clear what each group would use the resource for.
 - d. Vague statements like "we look forward to collaborating with this resource" or "we would be interested in open communication" are unacceptable and need to make more clear that they would use the resource if funded.
 - a. General letters of "enthusiastic support" must be deleted. Letters that do not qualify as Letters of Interest or Letters of Commitment for Funding must be removed.
 - a. Only 3-5 letters for academic and 3-5 letters from industry sources are allowed. All additional letters must be removed.

If your application materials do not meet these criteria, your application cannot move forward to our external review panel.

Your application has been placed in draft mode and you will have the opportunity to amend your application until **Wednesday, December 10th** at 5:00 PM. Please amend your application and/or take this as an opportunity to double check that you've appropriately addressed each question and sub-question, as well as uploaded all required attachments.

If you have any questions, please feel free to contact me.

Best,
Audrey (Medeiros) Byrne

Audrey (Medeiros) Byrne, PhD

Program Manager, Scientific Innovation & Strategic Investments

M: 774.721.4816 | Website: masslifesciences.com

Address: 1075 Main St Suite 100, Waltham MA 02451

Explore MLSC Funding Opportunities | [Learn more](#)
Become an expert reviewer for our programs | [Interest form](#)



The information contained in this communication, including any attachments, is confidential and is intended only for the use of the recipient(s) named above. If the reader of this message is not an intended recipient, you are notified that any dissemination, distribution or copying of this communication is strictly prohibited. If you receive this communication in error, please notify the sender immediately, and delete the communication, any attachments, and all copies. While certain exceptions and/or exemptions may apply, Massachusetts Public Records Laws and the Federal Freedom of Information Act governs this communication.

The information contained in this communication, including any attachments, is confidential and is intended only for the use of the recipient(s) named above. If the reader of this message is not an intended recipient, you are notified that any dissemination, distribution or copying of this communication is strictly prohibited. If you receive this communication in error, please notify the sender immediately, and delete the communication, any attachments, and all copies. While certain exceptions and/or exemptions may apply, Massachusetts Public Records Laws and the Federal Freedom of Information Act governs this communication.

The information contained in this communication, including any attachments, is confidential and is intended only for the use of the recipient(s) named above. If the reader of this message is not an intended recipient, you are notified that any dissemination, distribution or copying of this communication is strictly prohibited. If you receive this communication in error, please notify the sender immediately, and delete the communication, any attachments, and all copies. While certain exceptions and/or exemptions may apply, Massachusetts Public Records Laws and the Federal Freedom of Information Act governs this communication.

The information contained in this communication, including any attachments, is confidential and is intended only for the use of the recipient(s) named above. If the reader of this message is not an intended recipient, you are notified that any dissemination, distribution or copying of this communication is strictly prohibited. If you receive this communication in error, please notify the sender immediately, and delete the communication, any attachments, and all copies. While certain exceptions and/or exemptions may apply, Massachusetts Public Records Laws and the Federal Freedom of Information Act governs this communication.

RE: IMPORTANT: MLSC Research Infrastructure Application Revisions

From Orli Biger <Orli.Biger@arcinnovation.org>

Date Wed 2025-12-10 4:26 PM

To Carla Reimold <CReimold@masslifesciences.com>; ofira zloto <ozloto@gmail.com>; Audrey Medeiros <amedeiros@masslifesciences.com>

Cc Yonatan Keschner <ykeschner@arcinnovation.org>

 1 attachment (76 KB)

ARC Port Boston;

Dear Carla and Audrey,

I hope this email finds you well.

As a follow-up from our recent conversations, please find attached a confirmation email from our legal advisor stating that their office is actively working on the formation of ARC PORT Boston as a nonprofit organization based in Massachusetts.

We greatly appreciate your consideration of our application and kindly request the opportunity to edit the application as per your instructions.

Your assistance in temporarily reopening the application for revisions would be invaluable.

Thank you for your support and understanding.

Best regards,
Orli.

Orli Biger

CEO, ARC US

ARC Innovation at Sheba Medical Center



Orli.biger@arcinnovation.org

Mobile: 972-50-7089362

+1-615-971-4979

From: Carla Reimold <CReimold@masslifesciences.com>
Sent: Wednesday, December 10, 2025 11:22 AM
To: ofira zloto <ozloto@gmail.com>
Cc: Orli Biger <Orli.Biger@arcinnovation.org>; Audrey Medeiros <amedeiros@masslifesciences.com>
Subject: Re: IMPORTANT: MLSC Research Infrastructure Application Revisions

That works well for me. Speak soon!
Best,
Carla

Carla Reimold, PhD

Executive Vice President

Scientific Innovation and Strategic Investments

O: 781.373.7714 **M:** 781.296.9967



masslifesciences.com

1075 Main St Suite 100, Waltham MA 02451

From: ofira zloto <ozloto@gmail.com>
Sent: Wednesday, December 10, 2025 12:19 PM
To: Carla Reimold <CReimold@masslifesciences.com>
Cc: Orli Biger <Orli.Biger@arcinnovation.org>; Audrey Medeiros <amedeiros@masslifesciences.com>
Subject: Re: IMPORTANT: MLSC Research Infrastructure Application Revisions

Thank you. Can we speak at 13:00 o'clock today?
My phone number is-+16176089270

On Wed, 10 Dec 2025, 12:07 Carla Reimold, <CReimold@masslifesciences.com> wrote:

Dear Dr. Zloto,
Would you have time to hop on a quick call between 1pm and 4pm, to discuss?
Best,
Carla

Carla Reimold, PhD

Executive Vice President

Scientific Innovation and Strategic Investments

O: 781.373.7714

M: 781.296.9967



masslifesciences.com

1075 Main St Suite 100, Waltham MA 02451

From: ofira zloto <ozloto@gmail.com>
Sent: Wednesday, December 10, 2025 06:24
To: Audrey Medeiros <amedeiros@masslifesciences.com>
Cc: Orli Biger <Orli.Biger@arcinnovation.org>
Subject: Re: IMPORTANT: MLSC Research Infrastructure Application Revisions

Dear Audrey,

Thank you very much for your prompt reply.

Recently, our legal and administrative teams have been working to provide the required documentation confirming that ARC Boston will be eligible as a nonprofit entity. We expect to share this letter in the near future, in line with our previous conversation.

In the meantime, we have the three LOIs as requested (attached). In addition, we would like to update the Sharing/IP section (Section 7c) in accordance with the guidance provided during the webinar and e mail, as well as make a few additional technical adjustments to the application.

Given this, I would greatly appreciate it if you could temporarily reopen the application for the next 24-48 hours so we can incorporate these revisions, with the understanding that the documentation will be required in order for the committee to consider the ARC Boston proposal.

Thank you again for your assistance.

Best regards,
Prof. Ofira Zloto

On Tue, Dec 9, 2025 at 5:14 PM Audrey Medeiros <amedeiros@masslifesciences.com> wrote:

Hi Dr. Zloto,

As we haven't received the documentation that you are an eligible nonprofit, we have not reopened your application for editing.

Best,
Audrey

Audrey (Medeiros) Byrne, PhD

Program Manager, Scientific Innovation & Strategic Investments

M: 774.721.4816 | **Website:**

masslifesciences.com

Address: 1075 Main St Suite 100, Waltham MA 02451

Explore MLSC Funding Opportunities | [Learn more](#)

Become an expert reviewer for our programs | [Interest form](#)



From: ofira zloto <ozloto@gmail.com>

Sent: Monday, December 8, 2025 22:25

To: Audrey Medeiros <amedeiros@masslifesciences.com>

Cc: Orli Biger <Orli.Biger@arcinnovation.org>

Subject: Re: IMPORTANT: MLSC Research Infrastructure Application Revisions

Dear Audrey,

Thank you for the guidance provided in your recent email and during the webinar. I am working to implement all the relevant revisions to our Research Infrastructure application; however, the system does not allow me to make any edits, as the application status remains marked as "Received" (attached).

In order to proceed with the required updates, I kindly request that you change the status of our submission back to Draft (or otherwise reopen it for editing) and share the appropriate editable link.

Given that the revised submission deadline has been extended by MLSC to December 10, I would greatly appreciate your assistance as soon as possible so that we can ensure the application fully aligns with the program requirements.

Thank you,

Best regards,

Prof. Ofira Zloto

0016

Submitted to **Massachusetts Life Sciences Center - Research Infrastructure Program FY26** on Fri, Nov 21, 2025 1:34 PM

[Download](#) | [Withdraw](#) | [Transfer Ownership](#)

ACTIVITY MESSAGES FORMS NOTE AWARDS & PAYMENTS

Eligibility Form

No form submitted

Initial Form: Massachusetts Life Sciences Center

Research Infrastructure Program FY26
Submitted on November 21, 2025

Applicant Name (Organization)

On Thu, Dec 4, 2025 at 6:32 PM Audrey Medeiros <amedeiros@masslifesciences.com> wrote:

Hi all,

In order to expand on the content of my previous Research Infrastructure application email, I will be holding two sessions to go over the content of the email in more detail. Please register for one of the below sessions:

- [Register for Friday December 5th from 12pm-12:30pm](#)
- [Register for Monday December 8th from 9am-9:30am](#)

I will be expanding on the points in my previous email and will only be answering general questions, not questions regarding anyone's specific applications. Hope to see you all there!

Best,
Audrey

Audrey (Medeiros) Byrne, PhD

Program Manager, Scientific Innovation & Strategic Investments

M: 774.721.4816 | **Website:**

masslifesciences.com

Address: 1075 Main St Suite 100, Waltham MA 02451

Explore MLSC Funding Opportunities | [Learn more](#)

Become an expert reviewer for our programs | [Interest form](#)



From: Audrey Medeiros <amedeiros@masslifesciences.com>

Sent: Wednesday, December 3, 2025 16:59

To: Audrey Medeiros <amedeiros@masslifesciences.com>

Cc: Meghan Davis <mdavis@masslifesciences.com>

Subject: IMPORTANT: MLSC Research Infrastructure Application Revisions

Dear Research Infrastructure Program Applicant,

This is a copy of the message just sent through Submittable. MLSC staff has briefly reviewed submitted applications to determine eligibility for the program. Several applications require attention on one or more of the below points. **This is a general email going out to all applicants, and it does not mean your specific application requires revision.** Nevertheless, please review your application and ensure it meets all of the following requirements:

1. Biosketch/CVs: Each CV should be no more than 2 pages. If you have more than 3 CVs, please remove the additional CVs.
2. Sharing/IP: Please ensure to check your sharing plan (7c).
 - a. The resource cannot be limited to your institution, region, or collaborators. This section should explicitly mention that it is available to all researchers internal and external.
 - b. Use of the resource cannot be prioritized based on subjective metrics like project impact.
 - c. This answer should include how research use will occur, either direct usage or on a fee-for-service basis.
 - d. There cannot be IP restrictions on user data.
3. Budgets:
 - a. Please ensure it is clear that everything in your budget is a capital expense. See the Funding section on the [Eligibility Requirements and Evaluation Webpage](#) for more details on what qualifies as a capital expense.
 - b. Service contracts are only allowable when purchased with the equipment. Service contracts and warranties purchased outside of the initial equipment purchase are not allowed and must be removed from budgets.
 - c. Please check your MLSC budget tables and ensure that there are no \$ or commas. Check to be sure the row 4 "Total Contribution" cell has added correctly.
4. Cost share: Breakdown of Expenditures: Academic Contributions and Industry Contributions
 - a. The committed amounts in these two tables need to be explicitly documented as committed funds in an attached letter (Letters of Commitment from Funding Sources). Letters of funding commitment are required to have the dollar amount committed in them, and this amount needs to match the contributions table.
 - b. These commitment letters are not commitments from users. Grants of users are not acceptable as contributions and need to be removed. NIH grants are only allowable as cost-share if they are purchasing equipment or supplies directly to build/augment the core.
 - c. Additional letters of Commitment that do not contain the financial support and any general letters of support need to be removed.
5. Letters of Interest: Letters of Interest from academic and industry partners are required to say that they would actually use the resource and what they would use it for.
 - a. Each letter of interest is required to contain the following two components:
 - i. That they would utilize the equipment/resource
 - ii. An example of what project they would utilize the resource for
 - b. Letters from equipment vendors are not acceptable as letters of interest unless that company is planning to be a user of the resource.
 - c. Letters from a Chief or Dean of a department that say generally that their department would use this resource are unacceptable. Departmental letters that include multiple PI's need to be clear what each group would use the resource for.

- d. Vague statements like "we look forward to collaborating with this resource" or "we would be interested in open communication" are unacceptable and need to make more clear that they would use the resource if funded.
- a. General letters of "enthusiastic support" must be deleted. Letters that do not qualify as Letters of Interest or Letters of Commitment for Funding must be removed.
- a. Only 3-5 letters for academic and 3-5 letters from industry sources are allowed. All additional letters must be removed.

If your application materials do not meet these criteria, your application cannot move forward to our external review panel.

Your application has been placed in draft mode and you will have the opportunity to amend your application until **Wednesday, December 10th** at 5:00 PM. Please amend your application and/or take this as an opportunity to double check that you've appropriately addressed each question and sub-question, as well as uploaded all required attachments.

If you have any questions, please feel free to contact me.

Best,
Audrey (Medeiros) Byrne

Audrey (Medeiros) Byrne, PhD

Program Manager, Scientific Innovation & Strategic Investments

M: 774.721.4816 | **Website:**
masslifesciences.com

Address: 1075 Main St Suite 100, Waltham MA
02451

Explore MLSC Funding Opportunities | [Learn more](#)
Become an expert reviewer for our programs | [Interest form](#)



The information contained in this communication, including any attachments, is confidential and is intended only for the use of the recipient(s) named above. If the reader of this message is not an intended recipient, you are notified that any dissemination, distribution or copying of this communication is strictly prohibited. If you receive this communication in error, please notify the sender immediately, and delete the communication, any attachments, and all copies. While certain exceptions and/or exemptions may apply, Massachusetts Public Records Laws and the Federal Freedom of Information Act governs this communication.

The information contained in this communication, including any attachments, is confidential and is intended only for the use of the recipient(s) named above. If the reader of this message is not an intended recipient, you are notified that any dissemination, distribution or copying of this communication is strictly prohibited. If you receive this communication in error, please notify the sender immediately, and delete the communication, any attachments, and all copies. While certain exceptions and/or exemptions may apply,

Massachusetts Public Records Laws and the Federal Freedom of Information Act governs this communication.

The information contained in this communication, including any attachments, is confidential and is intended only for the use of the recipient(s) named above. If the reader of this message is not an intended recipient, you are notified that any dissemination, distribution or copying of this communication is strictly prohibited. If you receive this communication in error, please notify the sender immediately, and delete the communication, any attachments, and all copies. While certain exceptions and/or exemptions may apply, Massachusetts Public Records Laws and the Federal Freedom of Information Act governs this communication.

The information contained in this communication, including any attachments, is confidential and is intended only for the use of the recipient(s) named above. If the reader of this message is not an intended recipient, you are notified that any dissemination, distribution or copying of this communication is strictly prohibited. If you receive this communication in error, please notify the sender immediately, and delete the communication, any attachments, and all copies. While certain exceptions and/or exemptions may apply, Massachusetts Public Records Laws and the Federal Freedom of Information Act governs this communication.